Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2


The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval The vaccine supply for the EU would be produced by BioNTech’s manufacturing sites in Germany […]

Click here to view original web page at





Recommended Stories